Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
EUROHEALTH, February 5 - the State Drug Administration (nmpa) has approved the first-line clinical trial of the company's independently developed Bruton tyrosine kinase (Btk) inhibitor, orbotinib, combined with R-CHOP, in the treatment of mantle cell lymphoma (MCL), a biomedical company, announced today.
Obutinib is a class 1 innovative drug independently developed by ncjh. It is a new Btk inhibitor for the treatment of lymphoma and autoimmune diseases. On December 25, 2020, obutinib was approved by nmpa for the treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients and relapsed / refractory MCL patients. On December 31, 2020, obutinib was awarded orphan drug designation by the US Food and Drug Administration for the treatment of mantle cell lymphoma (MCL).
This text is a result of machine translation.
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Mar 01, 2021 11:55 AM
· Healthcare
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Healthcare, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Industrials, Financials, Consumer StaplesLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Briefing Dec 16, 2020 02:27 PM
· Healthcare
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 20, 2020 08:14 PM
· Healthcare
Pfizer submitted to FDA for authorization of emergency use of new crown vaccine
Briefing Nov 20, 2020 11:57 AM
· Healthcare
The new crown vaccine developed by academician Chen Wei and kangxinuo biology can be stable for a long time from 2 to 8 degrees
Briefing Nov 19, 2020 10:22 AM
· Healthcare
Geli pharmaceutical: asc40 (tvb-2640) China has completed phase II NASH patients
See more
Read next
In depth
Technology
Huawei 'Strikes Back': Global 5G Patent Battle Might Be Getting Started
Apr 18, 2021 10:53 PM
Financials · Analysis
Digital Currency Electronic Payment: Not A Warning Sign for Alipay and WeChat Pay
Apr 16, 2021 10:07 AM
Insight
Technology, Communication
Three Opportunities Brought by Archegos Capital's Outburst
Apr 12, 2021 12:31 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.